Nachrichten und Videos - WINDTREE THERAPEUTICS INC. - Englisch

Windtree Receives Notice of Delisting from NASDAQ - Common Stock to Begin Trading on OTCQB® Market Effective May 5, 2017 - PR Newswire WARRINGTON, Pa., May 3, 2017 WARRINGTON, Pa. , May 3, 2017 /PRNewswire/ -- Windtree Therapeutics, Inc. (Nasdaq: WINT), a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, today announced that it has received written notification from the NASDAQ Stock Market ("NASDAQ") that it has determined to delist the...

Windtree Announces Successful Completion of Second and Final AEROSURF® Phase 2b Clinical Trial Interim Safety Review -DSMB Recommends Continued Enrollment in AEROSURF Phase 2b Clinical Trial Without Modifications- -Company Remains on Track to Release Phase 2b Results Mid-Year 2017- PR Newswire WARRINGTON, Pa., April 11, 2017 WARRINGTON, Pa. , April 11, 2017 /PRNewswire/ -- Windtree Therapeutics, Inc. (Nasdaq: WINT), a biotechnology company focused on developing aerosolized KL4 surfactant...

Windtree Therapeutics Reports Fourth Quarter 2016 Financial Results and Provides Key Business Updates Company Continues to Advance Phase 2 Program and is On-Track for Mid-Year Phase 2b Results PR Newswire WARRINGTON, Pa., March 31, 2017 WARRINGTON, Pa. , March 31, 2017 /PRNewswire/ -- Windtree Therapeutics, Inc. (Nasdaq: WINT), a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, today reported financial results for the fourth quarter ended...

Windtree Therapeutics' Aerosolized KL4 Surfactant Reduces Lung Inflammation and Improves Survival in a High-Pathogen Avian Influenza Preclinical Study PR Newswire WARRINGTON, Pa., Feb. 16, 2017 WARRINGTON, Pa. , Feb. 16, 2017 /PRNewswire/ -- Windtree Therapeutics, Inc. (Nasdaq: WINT), a biotechnology company focusing on developing aerosolized KL4 surfactant therapies for respiratory diseases, announced today that data from a preclinical influenza study showed that aerosolized KL4 surfactant...

Windtree Therapeutics Completes $10.5 Million Private Offering Company Now Adequately Funded Through AEROSURF® Phase 2b Data in Mid-2017 PR Newswire WARRINGTON, Pa., Feb. 15, 2017 WARRINGTON, Pa. , Feb. 15, 2017 /PRNewswire/ -- Windtree Therapeutics, Inc. (Nasdaq: WINT), a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, today announced that it has completed a $10.5 million private placement of convertible preferred stock units and now...

Windtree Therapeutics to Host a Conference Call and Webcast at 8:00 AM on Thursday, February 16, 2017 to Provide Clinical and Financial Updates PR Newswire WARRINGTON, Pa., Feb. 15, 2017 WARRINGTON, Pa. , Feb. 15, 2017 /PRNewswire/ -- Windtree Therapeutics, Inc. (Nasdaq: WINT), a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, will host a conference call and webcast (including a slide presentation) at 8:00 AM EST on Thursday, February...

Windtree Therapeutics Announces Upcoming Presentations at Hot Topics in Neonatology Company to Present Two Posters at International Meeting for Neonatologists PR Newswire WARRINGTON, Pa., Dec. 1, 2016 WARRINGTON, Pa. , Dec. 1, 2016 /PRNewswire/ -- Windtree Therapeutics, Inc. (Nasdaq: WINT), a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, today announced that two abstracts have been accepted for presentation at the Hot Topics in...

Windtree Therapeutics' AEROSURF® (lucinactant for inhalation) Phase 2a Data Presented at the 2016 International Congress of Union of European Neonatal and Perinatal Societies AEROSURF Study Abstract Receives UENPS Congress 2016 Best Abstract Award PR Newswire WARRINGTON, Pa., Nov. 28, 2016 WARRINGTON, Pa. , Nov. 28, 2016 /PRNewswire/ -- Windtree Therapeutics, Inc. (Nasdaq: WINT), a biotechnology company focused on developing aerosolized KL 4 surfactant therapies for respiratory diseases, today...

Windtree Therapeutics to Present at Stifel 2016 Healthcare Conference PR Newswire WARRINGTON, Pa., Nov. 8, 2016 WARRINGTON, Pa. , Nov. 8, 2016 /PRNewswire/ -- Windtree Therapeutics, Inc. (Nasdaq: WINT), a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, today announced that Craig Frasier , President and Chief Executive Officer, will present at the Stifel 2016 Healthcare Conference at the Lotte New York Palace Hotel in New York. The...

Windtree Therapeutics Preclinical Study Results Show Potential for KL4 Surfactant as Possible Medical Countermeasure to Radiation Exposure Data Presented at the 62nd Radiation Research Society Annual Meeting PR Newswire WARRINGTON, Pa., Nov. 3, 2016 WARRINGTON, Pa. , Nov. 3, 2016 /PRNewswire/ -- Windtree Therapeutics, Inc. (Nasdaq:WINT), a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, announced today that recently presented preclinical...

Windtree Releases Data from Lung Deposition Study in Non-Human Primates Demonstrating Uniform Distribution of Aerosolized KL4 Surfactant in all Regions of the Lung Study Provides Further Validation of Company's Proprietary Aerosol Delivery Technology Management to Discuss Results on a Conference Call, Tuesday, October 25, 2016 at 8:00 a.m. PR Newswire WARRINGTON, Pa., Oct. 24, 2016 WARRINGTON, Pa. , Oct. 24, 2016 /PRNewswire/ -- Windtree Therapeutics, Inc. (Nasdaq: WINT), a biotechnology company...

Windtree Therapeutics to Host Conference Call and Webcast on Tuesday, October 25, 2016 to Provide a Business Update PR Newswire WARRINGTON, Pa., Oct. 20, 2016 WARRINGTON, Pa. , Oct. 20, 2016 /PRNewswire/ -- Windtree Therapeutics, Inc. (Nasdaq: WINT), a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, will host a conference call and webcast (including a slide presentation) at 8:00 a.m. EDT on Tuesday, October 25, 2016 to provide updates on...

Windtree Therapeutics Announces FDA Fast Track Designation for AEROSURF® PR Newswire WARRINGTON, Pa., Sept. 19, 2016 WARRINGTON, Pa. , Sept. 19, 2016 /PRNewswire/ -- Windtree Therapeutics, Inc. (Nasdaq: WINT), a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for AEROSURF® (lucinactant for inhalation) for the treatment of premature...